Activation-modulated DDS MCQs With Answer

Activation-modulated DDS MCQs With Answer

Introduction: Activation-modulated drug delivery systems (DDS) are advanced platforms engineered to release therapeutic agents in response to specific internal or external cues. This blog presents focused multiple-choice questions tailored for M.Pharm students studying MIP 103T – Novel Drug Delivery Systems. The questions explore underlying mechanisms (pH, temperature, enzymes, redox, light, magnetic and ultrasound triggers), materials (polymers, liposomes, hydrogels, nanoparticles), design strategies (linkers, thresholds, multi-stimuli systems), characterization techniques, and translational challenges. These MCQs emphasize conceptual understanding and practical considerations to reinforce learning and prepare students for examinations and research applications in stimulus-responsive drug delivery.

Q1. What best defines an activation-modulated drug delivery system?

• A drug delivery system that passively releases drug over time without external influence
• A drug delivery system that releases payload in response to specific endogenous or exogenous stimuli
• A formulation optimized only for extended shelf-life and stability
• A device that mechanically pumps drug at a constant rate

Correct Answer: A drug delivery system that releases payload in response to specific endogenous or exogenous stimuli

Q2. Which mechanism is most characteristic of pH-responsive polymers used in activation-modulated DDS?

• Photocleavage of covalent bonds under UV light
• Protonation/deprotonation leading to polymer swelling or cleavage of acid-labile bonds
• Magnetic alignment of polymer chains under a field
• Enzymatic hydrolysis by plasma esterases only

Correct Answer: Protonation/deprotonation leading to polymer swelling or cleavage of acid-labile bonds

Q3. For thermoresponsive polymers exhibiting a lower critical solution temperature (LCST), what occurs when the temperature rises above the LCST?

• The polymer becomes more hydrophilic and swells
• The polymer forms covalent crosslinks irreversibly
• The polymer becomes insoluble and collapses
• The polymer degrades into monomers

Correct Answer: The polymer becomes insoluble and collapses

Q4. Enzyme-responsive DDS commonly exploit which design element to achieve selective activation in diseased tissue?

• pH-sensitive hydrogen bonding networks
• Peptide linkers cleavable by disease-associated enzymes such as matrix metalloproteinases (MMPs)
• Thermal instability that melts at body temperature
• Magnetic nanoparticles embedded to generate heat

Correct Answer: Peptide linkers cleavable by disease-associated enzymes such as matrix metalloproteinases (MMPs)

Q5. Redox-responsive drug delivery systems most often rely on which intracellular trigger to release their payload?

• High extracellular calcium concentration
• Increased reactive oxygen species in plasma
• Reductive cleavage of disulfide bonds by intracellular glutathione
• Photodegradation by ambient light

Correct Answer: Reductive cleavage of disulfide bonds by intracellular glutathione

Q6. Which wavelength range is preferred for light-triggered DDS to achieve deeper tissue penetration with minimal photodamage?

• Ultraviolet (200–400 nm)
• Visible green light (500–550 nm)
• Near-infrared (NIR) light (700–900 nm)
• Far-infrared (>2500 nm)

Correct Answer: Near-infrared (NIR) light (700–900 nm)

Q7. How do magnetic-field-responsive DDS typically achieve on-demand drug release?

• By generating local heat via magnetic nanoparticles when exposed to an alternating magnetic field to trigger release
• By absorbing radiofrequency energy and emitting light
• By changing pH in response to the magnetic field
• By enzymatic activation through magnetized enzymes

Correct Answer: By generating local heat via magnetic nanoparticles when exposed to an alternating magnetic field to trigger release

Q8. What is a primary mechanism by which ultrasound can trigger drug release from a carrier system?

• Cavitation and mechanical disruption of the carrier increasing membrane permeability
• Direct photochemical bond cleavage induced by sound
• Magnetization of acoustic-responsive polymers
• Enzymatic activation localized to the ultrasound focal region

Correct Answer: Cavitation and mechanical disruption of the carrier increasing membrane permeability

Q9. Which strategy is commonly used in glucose-responsive insulin delivery to convert glucose concentration into a release signal?

• Incorporation of photosensitive dyes reacting with glucose
• Use of glucose oxidase to convert glucose to gluconic acid, lowering pH and triggering release
• Embedding magnetic beads that respond to glucose directly
• Relying solely on passive diffusion without a glucose-sensing element

Correct Answer: Use of glucose oxidase to convert glucose to gluconic acid, lowering pH and triggering release

Q10. What defines a prodrug approach in activation-modulated DDS?

• A pre-formed drug–carrier complex that degrades in the GI tract only
• An inactive derivative of a drug that is converted in vivo to the active form by enzymatic or chemical transformation
• A drug encapsulated in liposomes that leak slowly over time
• An antibody conjugate that remains permanently inactive

Correct Answer: An inactive derivative of a drug that is converted in vivo to the active form by enzymatic or chemical transformation

Q11. Which property is most critical for the linker used in an antibody–drug conjugate (ADC) intended for tumor-selective activation?

• Complete hydrolytic instability in serum
• Stability in systemic circulation and cleavage within the tumor microenvironment or intracellular compartment
• Non-cleavable in both circulation and target cells
• Cleavage only by ultraviolet light

Correct Answer: Stability in systemic circulation and cleavage within the tumor microenvironment or intracellular compartment

Q12. How do stimuli-responsive hydrogels typically regulate drug release on activation?

• By undergoing a reversible volume phase transition (swelling/deswelling) that controls diffusive pathways
• By converting drugs into gaseous forms for rapid escape
• By permanently crosslinking and entrapping the drug irreversibly
• By changing color to indicate release without altering diffusion

Correct Answer: By undergoing a reversible volume phase transition (swelling/deswelling) that controls diffusive pathways

Q13. Which statement correctly compares intracellular glutathione (GSH) and extracellular GSH concentrations relevant to redox-responsive DDS design?

• Intracellular GSH (~1–10 mM) is much higher than extracellular GSH (~2–20 µM)
• Extracellular GSH is higher (~5–10 mM) than intracellular (~10–50 µM)
• Both compartments have identical GSH concentrations around 1 mM
• GSH concentration is irrelevant for redox-triggered systems

Correct Answer: Intracellular GSH (~1–10 mM) is much higher than extracellular GSH (~2–20 µM)

Q14. Which analytical technique is most appropriate to determine thermal transitions such as glass transition or LCST in polymer-based activation-modulated DDS?

• Fourier-transform infrared spectroscopy (FTIR) only
• Differential scanning calorimetry (DSC)
• High-performance liquid chromatography (HPLC)
• Transmission electron microscopy (TEM)

Correct Answer: Differential scanning calorimetry (DSC)

Q15. Which release model best describes diffusion-controlled drug release from a homogeneous matrix where release is proportional to square root of time?

• Zero-order kinetic model
• First-order kinetic model
• Higuchi model
• Michaelis–Menten kinetics

Correct Answer: Higuchi model

Q16. The enhanced permeability and retention (EPR) effect is important for passive targeting of nanoparticles because:

• Tumors exhibit tightly closed vasculature that prevents nanoparticle entry
• Tumor vasculature is leaky and lymphatic drainage is poor, allowing nanoparticle accumulation
• Healthy tissues preferentially accumulate nanoparticles over tumors
• EPR causes immediate systemic clearance of nanoparticles

Correct Answer: Tumor vasculature is leaky and lymphatic drainage is poor, allowing nanoparticle accumulation

Q17. What is a major safety concern unique to activation-modulated DDS compared to conventional formulations?

• Complete lack of bioavailability in all cases
• Poor stability at refrigeration temperatures only
• Off-target or premature activation of the trigger leading to systemic toxicity
• Inability to encapsulate hydrophobic drugs

Correct Answer: Off-target or premature activation of the trigger leading to systemic toxicity

Q18. Which factor is often a bottleneck in translating stimulus-responsive DDS from lab to clinic?

• Excessive simplicity of manufacturing processes
• Manufacturing scale-up, reproducible batch-to-batch quality, and long-term stability concerns
• Universal regulatory pathways that are too permissive
• Too many clinical trials already proving safety

Correct Answer: Manufacturing scale-up, reproducible batch-to-batch quality, and long-term stability concerns

Q19. What is the principal advantage of dual- or multi-stimuli-responsive DDS compared with single-stimulus systems?

• They always release drug faster regardless of location
• They require multiple conditions to be met, increasing specificity and reducing premature release
• They are cheaper and simpler to produce
• They eliminate the need for any targeting ligands

Correct Answer: They require multiple conditions to be met, increasing specificity and reducing premature release

Q20. How can polymer molecular weight and crosslink density be used to tune drug release rates in activation-modulated DDS?

• Increasing molecular weight and crosslink density typically speeds up release by enlarging pores
• Increasing crosslink density or polymer molecular weight typically slows release by reducing diffusivity
• Crosslink density has no effect on diffusion; only drug chemistry matters
• Lower molecular weight polymers always produce zero-order release kinetics

Correct Answer: Increasing crosslink density or polymer molecular weight typically slows release by reducing diffusivity

Download